Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 3Active not recruiting 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Burkitt Lymphoma 7Meningeal Carcinomatosis 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 4Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Meningeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Uveal Melanoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Nevus 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Monocytic, Acute 1Leukemia, Hairy Cell 1Leukemia, Biphenotypic, Acute 1Hematopoietic and Lymphatic System Neoplasm 1Germinoma 1Down Syndrome 1Diabetes Insipidus 1Brain Neoplasms 1

Interventions

venetoclax 124Azacitidine 96Cytarabine 71fludarabine 44Specimen Handling 38Cyclophosphamide 38Daunorubicin 27Decitabine 26Biopsy 25Idarubicin 24Granulocyte Colony-Stimulating Factor 21gilteritinib 18Injections 18fludarabine phosphate 17Whole-Body Irradiation 17Melphalan 16Busulfan 16Stem Cell Transplantation 15Mycophenolic Acid 15ivosidenib 13Cladribine 13decitabine and cedazuridine drug combination 12Gemtuzumab 12Tacrolimus 11CPX-351 11X-Rays 10Filgrastim 10revumenib 9enasidenib 9Cyclosporine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Myeloid, Acute × Spinal Puncture × Clear all
NCT07012044 2026-05-27

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Recruiting
47 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06504459 2026-04-13

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

OHSU Knight Cancer Institute

Phase 2 Recruiting
40 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT06871410 2026-03-24

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Recruiting
26 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡